Resource Library
Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.
Related Resources
September 29, 2025
Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
European Respiratory Society (ERS) 2025 Congress – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025
The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models
European Academy of Dermatology & Venereology (EADV) 2025
Atopic Dermatitis (AD)
Asthma
Read More
May 19, 2025
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically
American Thoracic Society (ATS) 2025
May 17, 2025
Revolutionizing Immunology: Oral Medicines with Biologics-like Activity
American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
March 8, 2025
Clinical and Translational Science: Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults
Agarwal, et al.
October 25, 2024
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo
American College of Allergy, Asthma & Immunology (ACAAI) 2024
September 25, 2024
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo
European Academy of Dermatology and Venereology (EADV) 2024
August 16, 2024
Journal of Medicinal Chemistry: Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Zheng, et al.
July 29, 2024
Journal of Investigative Dermatology: Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers
McDonald, et al.
Hidradenitis Suppurativa (HS)
Read More